Abstract
While a great deal of information of drug-drug interactions is known, most concern Western drugs. Relatively little is known of the interactions between Western drugs and traditional drugs such as Kampo extract medicines (Japanese medicines modified from traditional Chinese medicines). This study investigated the effects of the marketed Kampo extract medicines, Senkyu-cha-cho-san and Sokei-kakketsu-to, on the intestinal absorption of CYP or P-glycoprotein (P-gp) in vivo. Midazolam, a CYP3A substrate drug, or talinolol, a P-gp substrate drug, was orally administered to rats with each of these Kampo extract medicines. Senkyu-cha-chosan or Sokei-kakketsu-to administered as a standard regimen did not obviously affect Cmax and area under the curve (AUC) of midazolam, although both Kampo extract medicines contained notopterol, a potent CYP3A4 inhibitor in vitro. The results implied a lack of potent drug-drug interactions between both Kampo extract medicines and CYP3A substrate drugs. Concomitant administration of each Kampo extract medicine unexpectedly showed the tendency to decrease Cmax and AUC of talinolol. Decreased intestinal absorption of talinolol might be caused, not by the inhibition of P-gp, but by the inhibition of organic anion transporting peptides by both Kampo extract medicines.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Benet, L. Z., Cummins, C. L., and Wu, C. Y., Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int. J. Pharm., 277, 3–9 (2004).
Cordon-Cardo, C., O’Brien, J. P., Casals, D., Rittman-Grauer, L., Biedler, J. L., Melamed, M. R., and Bertino, J. R., Multidrug-resistance gene (P-glycoprotein) is expressed by en dothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. U. S. A., 86, 695–698 (1989).
Cordon-Cardo, C., O’Brien, J. P., Boccia, J., Casals, D., Bertino, J. R., and Melamed, M. R., Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem. Cytochem., 38, 1277–1287 (1990).
de Castro, W. V., Mertens-Talcott, S., Derendorf, H., and Butterweck, V., Grapefruit juice-drug interactions: Grapefruit juice and its components inhibit P-glycoprotein (ABCB1) mediated transport of talinolol in Caco-2 cells. J. Pharm. Sci., 96, 2808–2817 (2007).
Dresser, G. K., Bailey, D. G., Leake, B. F., Schwarz, U. I., Dawson, P. A., Freeman, D. J., and Kim, R. B., Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin. Pharmacol. Ther., 71, 11–20 (2002).
Englund, G., Rorsman, F., Rönnblom, A., Karlbom, U., Lazorova, L., Gråsjö, J., Kindmark, A., and Artursson, P., Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur. J. Pharm. Sci., 29, 269–277 (2006).
Guo, L. Q., Fukuda, K., Ohta, T., and Yamazoe, Y., Role of furanocoumarin derivatives on grapefruit juice-mediated inhibition of human CYP3A activity. Drug Metab. Dispos., 28, 766–771 (2000a).
Guo, L. Q., Taniguchi, M., Xiao, Y. Q., Baba, K., Ohta, T., and Yamazoe, Y., Inhibitory effect of natural furanocoumarins on human microsomal cytochrome P450 3A activity. Jpn. J. Pharmacol., 82, 122–129 (2000b).
Iwanaga, K., Hayashi, M., Hamahata, Y., Miyazaki, M., Shibano, M., Taniguchi, M., Baba, K., and Kakemi, M., Furanocoumarin derivatives in Kampo extract medicines inhibit cytochrome P450 3A4 and P-glycoprotein. Drug Metab. Dispos., 38, 1286–1294 (2010a).
Iwanaga, K., Sumizawa, T., Miyazaki, M., and Kakemi, M., Characterization of organogel as a novel oral controlled release formulation for lipophilic compounds. Int. J. Pharm., 388, 123–128 (2010b).
Iwanaga, K., Yoneda, S., Hamahata, Y., Miyazaki, M., Shibano, M., Taniguchi, M., Baba, K., and Kakemi, M., Inhibitory effects of furanocoumarin derivatives in Kampo extract medicines on P-glycoprotein at the blood-brain barrier. Biol. Pharm. Bull., 34, 1246–1251 (2011).
Kageyama, M., Namiki, H., Fukushima, H., Ito, Y., Shibata, N., and Takada, K., In vivo effects of cyclosporin A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rats. Biol. Pharm. Bull., 28, 316–322 (2005).
Kakar, S. M., Paine, M. F., Stewart, P. W., and Watkins, P. B., 6″-Dihydroxybergamottin contributes to the grapefruit juice effect. Clin. Pharmacol. Ther., 75, 569–579 (2004).
Kanazu, T., Okamura, N., Yamaguchi, Y., Baba, T., and Koike, M., Assessment of the hepatic and intestinal first-pass metabolism of midazolam in a CYP3A drug-drug interaction model rats. Xenobiotica, 35, 305–317 (2005).
Kato, Y., Miyazaki, T., Kano, T., Sugiura, T., Kubo, Y., and Tsuji, A., Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol. J. Pharm. Sci., 98, 2529–2539 (2009).
Kono, T., Kanematsu, T., and Kitajima, M., Exodus of Kampo, traditional Japanese medicine, from the complementary and alternative medicines: is it time yet? Surgery, 146, 837–840 (2009).
Lemma, G. L., Wang, Z., Hamman, M. A., Zaheer, N. A., Gorski, J. C., and Hall, S. D., The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates. Clin. Pharmacol. Ther., 79, 218–230 (2006).
Meier, Y., Eloranta, J. J., Darimont, J., Ismair, M. G., Hiller, C., Fried, M., Kullak-Ublick, G. A., and Vavricka, S. R., Regional distribution of solute carrier mRNA expression along the human intestinal tract. Drug Metab. Dispos., 35, 590–594 (2007).
Paine, M. F., Widmer, W. W., Hart, H. L., Pusek, S. N., Beavers, K. L., Criss, A. B., Brown, S. S., Thomas, B. F., and Watkins, P. B., A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction. Am. J. Clin. Nutr., 83, 1097–1105 (2006).
Riegelman, S. and Collier, P., The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J. Pharmacokinet. Biopharm., 8, 509–534 (1980).
Schmiedlin-Ren, P., Edwards, D. J., Fitzsimmons, M. E., He, K., Lown, K. S., Woster, P. M., Rahman, A., Thummel, K. E., Fisher, J. M., Hollenberg, P. F., and Watkins, P. B., Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab. Dispos., 25, 1228–1233 (1997).
Schwarz, U. I., Gramatté, T., Krappweis, J., Oertel, R., and Kirch, W., P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. Int. J. Clin. Pharmacol. Ther., 38, 161–167 (2000).
Schwarz, U. I., Seemann, D., Oertel, R., Miehlke, S., Kuhlisch, E., Fromm, M. F., Kim, R. B., Bailey, D. G., and Kirch, W., Grapefruit juice ingestion significantly reduces talinolol bioavailability. Clin. Pharmacol. Ther., 77, 291–301 (2005).
Shirasaka, Y., Li, Y., Shibue, Y., Kuraoka, E., Spahn-Langguth, H., Kato, Y., Langguth, P., and Tamai, I., Concentration-dependent effect of naringin on intestinal absorption of beta(1)-adrenoceptor antagonist talinolol mediated by pglycoprotein and organic anion transporting polypeptide (Oatp). Pharm. Res., 26, 560–567 (2009).
Shirasaka, Y., Kuraoka, E., Spahn-Langguth, H., Nakanishi, T., Langguth, P., and Tamai, I., Species difference in the effect of grapefruit juice on intestinal absorption of talinolol between human and rat. J. Pharmacol. Exp. Ther., 332, 181–189 (2010).
Westphal, K., Weinbrenner, A., Giessmann, T., Stuhr, M., Franke, G., Zschiesche, M., Oertel, R., Terhaag, B., Kroemer, H. K., and Siegmund, W., Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clin. Pharmacol. Ther., 68, 6–12 (2000).
Yu, F., Takahashi, T., Moriya, J., Kawaura, K., Yamakawa, J., Kusaka, K., Itoh, T., Morimoto, S., Yamaguchi, N., and Kanda, T., Traditional Chinese medicine and Kampo: a review from the distant past for the future. J. Int. Med. Res., 34, 231–239 (2006).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Iwanaga, K., Arimune, K., Miyazaki, M. et al. Effects of furanocoumarins in Kampo extract-based medicines on rat intestinal absorption of CYP3A and P-glycoprotein substrate drugs in vivo . Arch. Pharm. Res. 35, 1055–1064 (2012). https://doi.org/10.1007/s12272-012-0613-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-012-0613-x